D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study Results

Li, ZM; Song, ZB; Zhao, YQ; Wang, PL; Jiang, LY; Gong, Y; Zhou, JY; Jian, H; Dong, XR; Zhuang, W; Cang, SD; Yang, N; Fang, J; Shi, JH; Lu, JG; Ma, R; Wu, P; Zhang, YQ; Song, MM; Xu, CW; Shi, Z; Zhang, L; Wang, YL; Wang, XC; Zhang, YP; Lu, S

Lu, S (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Sch Med, 241 West Huaihai Rd, Shanghai 200030, Peoples R China.

JOURNAL OF THORACIC ONCOLOGY, 2023; 18 (7): 940

Abstract

Introduction: D-1553 (garsorasib) is a potent and selective oral KRASG12C inhibitor. We report results from a phase I dose-escalation and dose-expansi......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索